Description

Vinpocetine Nootropic Powder

 

 

 

CAS Number	42971-09-5
Other Names	Cavinton, Ceractin, Apovincaminic Acid Ethyl Ester
IUPAC Name	Ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
Molecular Formula	C₂₂H₂₆N₂O₂
Molecular Weight	350.5
Purity	≥99% Pure (LC-MS)
Liquid Availability	N/A
Powder Availability	5 grams
Gel Availability	N/A
Storage	Store in cool dry environment, away from direct sunlight.
Terms	All products are for laboratory developmental research USE ONLY. Products are not for human consumption.

 

Vinpocetine is a compound most commonly found in the periwinkle plant. It is considered an ethyl ester of the compound apovincamine and derived from the alkaloid family. Vinpocetine has been shown to increase blood flow to the brain by improving mitochondrial functioning and utilization of glucose and oxygen, as well as inhibiting PDE1. Vinpocetine has shown promise in improving overall cognition and preventing various cerebrovascular disorders such as memory loss, stroke, and even cancer.

Many of the benefits of vinpocetine were initially linked back to its ability to improve blood flow to the brain. However, benefits such as improved cognition and memory have been found to be related to the mechanistic actions of PDE1 inhibition, enhancement of cGMP, and the effect the compound has on various ion channels. Animal studies have shown how inhibition of PDE1 can protect against neurotoxins, such as alcohol. A notable study reported the administration of 20 mg/kg of vinpocetine to rats which led to overall improvement of cognition and neuroprotection. Furthermore, studies have found that enhancement of cGMP assists in regulating neural plasticity, which is related to improvements in learning and memory loss. Additionally, vinpocetine has been shown to positively affect long term potentiation (LTP). In vitro studies examined hippocampal cross-sections in mice and found that a concentration of 0.1 µM was most effective in terms of regulating LTP.

The mechanisms of vinpocetine in terms of its relation to different ion channels are numerous. Vinpocetine seems to interact with many ion channels such as sodium, calcium, and potassium. These interactions tend to lead to a suppression in neurotransmitter release. However, this has been found to increase neuroprotective effects when neurotransmitters such as glutamate and dopamine are suppressed. Researchers have also theorized that vinpocetine is capable of modulating the effects of different ion channels. For example, evidence shows that manipulation of sodium and calcium channels can improve memory. That being said, since vinpocetine also has the potential to improve memory, researchers believe that the activity of the compound and the ion channels are directly related to each other. Further research should be conducted in order to determine the exact mechanism of action.

Various studies, primarily performed in rats, have examined the effect the vinpocetine has on memory. The results were measured by subjecting the animals to water, retrieval, and memory scanning tests. The first study cited by researchers Patel et. Al, examined the effects of vinpocetine on healthy mice and aged mice. The subjects were administered 10 mg/kg of vinpocetine daily and were put through a water test in order to test special memory. The healthy mice saw no benefit when given the compound, however, the older rats exhibited signs of improved memory.

The second cited study examined how vinpocetine affected memory retrieval in rats. The rats were given doses of either vinpocetine varying from 18 to 30 mg/kg daily, or doses of the primary metabolite of vinpocetine, apovincamic acid. Results were measured based on the rats’ performance on a step-down passive avoidance test. The rats receiving doses of vinpocetine experienced an improvement in memory retrieval, not dependent on the dosage. However, the mice receiving apovincamic acid saw little to no change in memory retrieval. The third study cited by Patel et. Al was only briefly mentioned, but it showed promising results regarding the effects of vinpocetine on memory. Results were measured by a memory scanning speed in adult, female rats. The subjects were administered doses ranging from 10-40 mg/kg daily. Improvements in scanning speed were noticed in the subjects receiving 40 mg/kg of vinpocetine, but not in those being administered 10-20 mg/kg. While these results are promising, further research should be conducted in order to determine if these results translate to other subject groups (https://examine.com/supplements/vinpocetine/research/#4J45Zl9-neurology-1_4J45Zl9-memory-and-cognition-1).

There is also strong evidence suggesting that vinpocetine can help combat against the formation of cancer cells. A study conducted by Huang et. Al found that proliferation of breast cancer cells was inhibited through the administration of vinpocetine. Research showed that the compound was able to stop the cell cycle at the G0/G1 phase which would not allow the cancer cells to mature and divide. Additionally, vinpocetine led to the attenuated activation of PI3K and STAT3, indicating that the compound led to the inhibition of cell viability. Additional studies have emphasized the probability that vinpocetine is capable of enhancing the effects of radiation by increasing the rate of tumor oxygenation (https://www.mskcc.org/cancer-care/integrative-medicine/herbs/vinpocetine).

The nootropics sold by Umbrella Labs are sold for laboratory research only. The description above is not medical advice and is for informative purposes only.

Vinpocetine is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.

 

File Name	View/Download
2024-03-15-Umbrella-Labs-Vinpocetine-Certificate-Of-Analysis-COA.pdf

 

 

VIEW CERTIFICATES OF ANALYSIS (COA)